Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Document Dump: Guidance Release Skyrocketed In Advance Of Trump

Executive Summary

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.

You may also be interested in...



Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’

Incoming president will not hold over any FDA political appointees from the Obama administration, but what exactly his stamp on the agency will be remains unclear.

FDA Cracks Open Door For More Manufacturer Communications

Two draft guidance documents would allow a broader range of communications with payers and others about information not included on device labeling, or concerning products without FDA approval.

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.

Related Content

Topics

UsernamePublicRestriction

Register

MT104352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel